FDA — authorised 30 August 2002
- Application: ANDA075478
- Marketing authorisation holder: BARR
- Status: supplemented
FDA authorised "Conventional" regimen on 30 August 2002
Yes. FDA authorised it on 30 August 2002; FDA authorised it on 24 February 2004.
BARR holds the US marketing authorisation.